Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...

Summit Therapeutics Inc. (NASDAQ: SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- The anti-inflammatory drugs market size has grown rapidly in recent years. From $136.86 billion in 2024, it is predicted to ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

AstraZeneca PLC logged a -2.4% change during today's morning session, and is now trading at a price of $69.45 per share. The ...

(Alliance News) - AstraZeneca PLC on Friday said Imfinzi is "poised to transform the standard of care" as it reported the bladder cancer treatment cleared a European regulatory milestone.

AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

Richard Childress Racing in the NASCAR Cup Series at the Chicago Street Race… NASCAR returns to Chicago for the sport’s only street race, which weaves through Chicago’s Grant Park area, artfully ...

London IPO fundraising hit a three-decade low in the first half of 2025, with only £160 million raised across five listings.